NCT05586724View on ClinicalTrials.gov

Micronized Progesterone Versus Norethisterone Acetate in Combination With Estrogen as Menopausal Hormone Therapy

PHASE3RecruitingINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2027

Conditions
Menopausal Symptoms
Interventions
DRUG

Micronized progesterone in continuous combination with oral estrogen

Capsule 100 mg mP (Utrogestan®) orally per day in continuous combination with 1 mg encapsulated estradiol (Estrofem®)

DRUG

Norethisterone acetate in continuous combination with oral estrogen

Capsule 0.5 mg NETA/ 1 mg estradiol (Activelle®) orally per day (encapsulated and identical to Estrofem® and one matched placebo to Utrogestan

Trial Locations (1)

171 76

RECRUITING

Karolinska University Hospital, Stockholm

All Listed Sponsors
lead

Angelica Lindén Hirschberg

OTHER